clinical trial

  •   George Lundberg, MD

    This piece from the scientific journal Nature Medicine describes a new clinical trial studying vaccination against COVID-19 specifically in patients with cancer. 

    .

  •   George Lundberg, MD

    Fewer patients with cancer may be willing to enter a clinical trial. This Cancer Network article explains why and offers solutions.

    .

  •   George Lundberg, MD

    This list from the National Cancer Institute outlines many government-supported clinical trials for COVID-19 that may be specifically for cancer survivors.

    .

  •  

    Behind the Scenes at Cancer Commons: Working with Patients

    With: Emma Shtivelman, PhD

    Cancer Commons helps advanced cancer patients identify and access their best-possible treatments. Here, our Curious Dr. George asks Chief Scientist Emma Shtivelman, PhD, for an inside look at how she helps the people who turn to us for guidance. Curious Dr. George: As Chief Scientist at Cancer Commons for many years, you have helped thousands of patients with advanced cancer… Read more »

  •  

    What Is a Cancer Commons Options Report?

    With: Lola Rahib, PhD

    As a Cancer Commons Scientist, Lola Rahib, PhD, helps cancer patients and caregivers navigate treatment. Some of these patients receive a Cancer Commons Options Report. Here, our Curious Dr. George asks Dr. Rahib to share what goes into each Options Report. Curious Dr. George: Cancer Commons provides advanced cancer patients who seek information with additional options for them to consider, all… Read more »

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Acute myeloid leukemia is a particularly difficult-to-treat form of leukemia. There are standard treatments, but it may be best for a patient to consider a clinical trial early on. This article from Medscape clearly specifies diagnostic and therapeutic options.

    .

  •  

    Can Preclinical Data Guide Clinical Cancer Therapy?

    With: Keith Flaherty, MD

    A Q&A with Keith Flaherty, MD, Associate Professor of Medicine, Harvard Medical School; Director of Developmental Therapeutics, Cancer Center, Massachusetts General Hospital; kflaherty@mgh.harvard.edu Originally published Aug 31, 2016 Q: Under what circumstances and to what extent are you willing to take clinical actions on a cancer patient based primarily on preclinical data? A: There are two scenarios that come to… Read more »

  •  
  •  

    New Glioblastoma Trial Adds Whole-Brain Irradiation to Plerixafor

    With: Martin Brown, D.Phil, FASTROLawrence Recht, MD

    A Q&A with Martin Brown, D.Phil, FASTRO, Emeritus Professor (mbrown@stanford.edu), and Lawrence Recht, MD, Professor, at Stanford University’s Department of Neurology (lrecht@stanford.edu) Q: The treatment of glioblastoma multiforme (GBM) is a serious challenge. Recurrence after initial surgery is common and subsequent treatment almost always unsuccessful. Just as “an army marches on its stomach,” GBM growth depends on blood supply. Successful… Read more »

  •   Emma Shtivelman, PhD

    Excerpt:

    The Lung Cancer Master Protocol (Lung-MAP), the first precision medicine trial in lung cancer supported by the National Cancer Institute (NCI), is undergoing a major expansion to include patients with all non–small cell lung cancers (NSCLCs).

    “The trial previously tested treatments for people with advanced-stage squamous cell lung cancer. Opening the trial to all types of advanced-stage NSCLCs means that thousands of new patients will be eligible to enroll.”

    Go to full article published by The ASCO Post on Feb 1, 2019.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.